FOUNDERS

Gerard Honig, PhD       Chief Executive Officer

Gerard founded Symbiotic Health in 2013 to develop microbiome-based therapeutics to address critical public health challenges. He directs all aspects of the company’s strategy and operations. He has received numerous awards for this work, including the FIGHT CDIFF Innovator’s Award from the Peggy Lillis Memorial Foundation. Gerard, a New York native, received his bachelor’s degree from Columbia University and received a PhD in Biological Sciences from the University of California, San Francisco, where he held a Howard Hughes Medical Institute fellowship. He later worked in microbiome research and pathogenesis with Dan Littman and Betty Diamond.

Bruce Hirsch, MD FACP AAHIVS       Vice President for Clinical Affairs

Bruce advises the company on clinical affairs. He has served as attending faculty at North Shore University Hospital for over 25 years, and has held multiple leadership positions within the Northwell Health system. Bruce received his MD from Cornell University and trained in geriatrics and infectious disease at North Shore University Hospital, Cornell and Albert Einstein. He is Assistant Professor of Infectious Diseases in the Hofstra Northwell School of Medicine. Bruce has developed novel clinical modalities of microbiome transplantation for the treatment of gut infections. He has a long-standing interest in innovative therapeutics, serves on the North Shore University Hospital Committee on Pharmacy and Therapeutics, and holds a patent for an infection control device.


Management Team

Gerard Honig, PhD       Chief Executive Officer

Gerard founded Symbiotic Health in 2013 to develop microbiome-based therapeutics to address critical public health challenges. He directs all aspects of the company’s strategy and operations. He has received numerous awards for this work, including the FIGHT CDIFF Innovator’s Award from the Peggy Lillis Memorial Foundation. Gerard, a New York native, received his bachelor’s from Columbia University and received a PhD in Biological Sciences from the University of California, San Francisco, where he held a Howard Hughes Medical Institute fellowship. He later worked in microbiome research and pathogenesis with Dan Littman and Betty Diamond.

Noel Goddard, PhD       Chief Technology Officer

Noel directs the development of Symbiotic Health's formulation and manufacturing technologies.   Noel has a broad research background in biophysics, materials and instrument design.  She received her PhD in Physics & Biology at Rockefeller University and continued her postdoctoral research as a Junior Fellow at Harvard University.   Noel returned to New York to serve as an assistant professor of physics at Hunter College, CUNY where she directed an interdisciplinary research laboratory and developed the college's biophysics curriculum.  She is also the founder and CEO of Goddard Labs Inc., a molecular diagnostic company focused on pathogen detection in food.

Stephen Popielarski, PhD   Vice President for Commercial Development

Stephen directs commercialization strategy, drawing on his extensive experience developing and executing on strategies across the product lifecycle at biomedical companies including GeneOhm and J&J. He has successfully established new business models, developed and launched new products, and managed product portfolios as large as $2.3 billion. Steve is currently Managing Partner of SPHM Enterprises LLC, a marketing and strategy consultancy. He received his PhD in Chemical Engineering from Caltech with a focus on drug delivery systems.


Board of Directors

Gerard Honig, PhD       Chief Executive Officer

Gerard founded Symbiotic Health in 2013 to develop microbiome-based therapeutics to address critical public health challenges. He directs all aspects of the company’s strategy and operations. He has received numerous awards for this work, including the FIGHT CDIFF Innovator’s Award from the Peggy Lillis Memorial Foundation. Gerard, a New York native, received his bachelor’s from Columbia University and received a PhD in Biological Sciences from the University of California, San Francisco, where he held a Howard Hughes Medical Institute fellowship. He later worked in microbiome research and pathogenesis with Dan Littman and Betty Diamond.

Kathryn Stein, PhD     Principal, Kathryn Stein Consulting, LLC

Kathryn Stein is an accomplished scientist, regulatory official and drug development executive. Dr. Stein was the first director of the FDA’s Division of Monoclonal Antibodies, where she led the development of regulatory policies for novel biotechnology products and approval of the early monoclonal antibody products. While at the FDA, she led a productive immunology research program developing bacterial products (polysaccharide-protein conjugate vaccines).  From 2002 through January 2016, Kathryn served as Vice President and Senior Vice President of Product Development and Regulatory Affairs at MacroGenics, Inc., where she established product development and regulatory affairs, project management, quality and manufacturing departments.  She currently provides strategic advice and guidance for multiple therapeutics companies.  She received a BA in chemistry from Bard College and a PhD in microbiology and immunology from the Albert Einstein College of Medicine. She has received numerous awards for her long-standing achievements, including the FDA Center for Biologics Evaluation and Research Outstanding Service Award. She was the 2014 recipient of the John and Samuel Bard Award in Medicine and Science from Bard College.

Steven Winick   Managing Director, Topspin Partners

Steve Winick is Managing Director of the venture arm of Topspin Partners. He came to Topspin from Honeywell, Intl., where he most recently served as CIO of its $2 billion security group.  He had been with Honeywell for over 21 years as CTO of the security business, as well as founder and president of its wireless communications services business.  He presently serves as a director of Thermolift, Inc., Celmatix, Inc., Setpoint Medical, Inc., Mirimus, Inc., GenDX, Inc. and Certerra, Inc.  Mr. Winick received a BS in Economics and Electrical Engineering from the University of Pennsylvania. He received his law degree from Georgetown University Law Center and is a member of the Bar of the State of New York.

Leo Guthart, DBA   Founder & CEO, Topspin Partners (Board Observer)

Leo Guthart is the founder and Chief Executive Officer of Topspin Partners. Prior to founding Topspin, Dr. Guthart was President, CEO and Chairman of Ademco Security Group. Under his tenure, the company grew from a fledgling manufacturer to one of the world’s largest manufacturer and distributor of security systems. Dr. Guthart served as director of Aragon Pharmaceuticals (sold to Johnson & Johnson) and Seragon Pharmaceuticals (sold to Roche-Genentech). He is presently a Director of Peloton Pharmaceuticals.  Dr. Guthart currently serves as a trustee of Cold Spring Harbor Laboratory, Hofstra University and the Stony Brook Foundation.  Dr. Guthart received a bachelor’s degree in physics and master’s and doctorate in business administration from Harvard University.


Scientific Advisors

Vincent Fischetti, PhD    

Head of Laboratory of Bacterial Pathogenesis and Immunology,   Rockefeller University

Dr. Fischetti directs the Laboratory for Bacterial Pathogenesis and Immunology at Rockefeller University.  He is a thought leader in the field of antimicrobial resistance. His work has led directly to the development of several novel antimicrobials, including a clinical-stage recombinant lysin enzyme for MRSA infection. Dr. Fischetti is the holder of 40 U.S. patents. Among other distinctions, he is a trustee and the chair of the scientific advisory board of the Trudeau Institute and is the former editor-in-chief of the scientific journal Infection and Immunity. He has been faculty at Rockefeller University since 1973.

Larry Miller, MD          Chief of Gastroenterology, North Shore University Hospital & Long Island Jewish Hospital, Northwell Health system

Larry is a leading physician, physiologist, inventor and innovator in the translational GI space. His accomplishments span the fields of GI, endoscopy, nutrition, obesity and medical device development. He has directed a highly active bench-to-bedside research program for over 20 years, performing extensive animal model experiments and clinical proof-of-concept interventional clinical trials in functional GI. He has invented several medical devices for therapeutic GI indications. He is a leader in nuclear imaging applications in GI research. He also has a long-standing interest in the microbiome and has published a proof-of-concept study on the role of intestinal bacteria in Irritable Bowel Syndrome.

Joanne Willey, PhD          Chair of Science Education, Hofstra Northwell School of Medicine

Joanne is a microbiologist with broad and deep experience in academic and industrial R&D. She is currently the Chair of Science Education at the Hofstra/NorthShoreLIJ School of Medicine and has served as faculty at Hofstra for over 20 years. Joanne advises Symbiotic on microbial physiology and experimental design. In the summer of 2015, she will increase her time commitment to design and execute experimental work and train Symbiotic research staff. Joanne was named Distinguished Lecturer by the American Society of Microbiology in 2008.

Peter Kim, MD MMM FACS      Associate Professor of Surgery, Albert Einstein College of Medicine & Jacobi Medical Center

Dr. Kim received his bachelor's degree from Harvard College, his medical degree from Cornell and his general surgery residency training at the University of Pittsburgh. He has completed several research fellowships includes a Howard Hughes Medical Institute Fellowship at the NIH. He is actively engaged in surgery education and innovation in clinical practice, with a particular focus on the prevention and management of severe infections in the surgical setting.